Systemic diseases in myelodysplastic syndromes.

被引:18
|
作者
Hebbar, M
HebbarSavean, K
Fenaux, P
机构
来源
REVUE DE MEDECINE INTERNE | 1995年 / 16卷 / 12期
关键词
myelodysplastic syndrome; relapsing polychondritis; vasculitis; seronegative arthritis;
D O I
10.1016/0248-8663(96)80810-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelodysplastic syndromes (MDS) are characterized by quantitative and functional involvement of myeloid lineages. Yet, systemic manifestations, suggestive of a lymphocytic involvement, have been described in MDS. We review here biological and clinical data concerning the associations between MDS and immunological disorders. Biological auto-immune markers are in fact rare in MDS, and especially encountered in the chronic myelomonocytic leukemia subgroup. Only a few systemic diseases seem to be frequently associated with MDS: seronegative arthritis, cutaneous vasculitis, and relapsing polychondritis. These diseases are probably not entirely auto-immune, and the signification of their association with an MDS remains nuclear. About 30% of relapsing polychondritis are associated with MDS. Conversely, 0.6% of MDS are associated with a relapsing polychondritis. These associations are mainly encountered in men suffering from a refractory anemia (with or without excess of blasts). The main cytogenetic abnormalities are monosomy 7, presence of a ring chromosome, and monosomy 16.
引用
收藏
页码:897 / 904
页数:8
相关论文
共 50 条
  • [31] Circulating dendritic cells of the patients with myelodysplastic syndromes.
    Shao, Zonghong
    Wang, Huaquan
    Xing, Limin
    Fu, Rong
    Tu, Fengmei
    BLOOD, 2007, 110 (11) : 221B - 221B
  • [32] Cytologic aspects and current nosography of myelodysplastic syndromes.
    Flandrin, G
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 545 - 549
  • [33] Delayed responses to thalidomide in patients with myelodysplastic syndromes.
    Lisak, LA
    Little, L
    Dean, L
    Ekbal, M
    duRandt, M
    Hussain, M
    Kaistha, V
    Raza, A
    BLOOD, 2000, 96 (11) : 261B - 261B
  • [34] Myelodysplastic syndromes. Incidence and survival in Republic of Armenia
    Daghbashyan, S.
    Sahakyan, L.
    Kabasakalyan, E.
    LEUKEMIA RESEARCH, 2013, 37 : S41 - S41
  • [35] Biologic characteristics of patients with hypocellular myelodysplastic syndromes.
    Goyal, R
    Qawi, H
    Ali, SI
    Dar, S
    Mundle, S
    Ahmed, B
    Quadri, M
    Naseer, OB
    Andrews, C
    Shetty, V
    Mativi, B
    Altampallam, K
    Lisak, L
    Loew, J
    Venugopal, P
    Gezer, S
    Robin, E
    Rifkin, S
    Raza, A
    BLOOD, 1998, 92 (10) : 629A - 629A
  • [36] Abnormal lipid profiles in patients with myelodysplastic syndromes.
    Allampallam, K
    Dutt, D
    Nair, C
    Shetty, V
    Mundle, S
    Lisak, L
    Andrews, C
    Ahmed, B
    Mazzone, L
    Zorat, F
    Borok, R
    Muzammil, M
    Akber, A
    Gundroo, A
    Ansaarie, I
    Raza, A
    BLOOD, 1999, 94 (10) : 282B - 282B
  • [37] Terminal deoxynucleotidyl transferase expression in myelodysplastic syndromes.
    Fan, G
    Mazzella, FM
    KowalVern, A
    Wibowo, A
    Mikhael, A
    Schumacher, HR
    BLOOD, 1997, 90 (10) : 4037 - 4037
  • [38] Phenotypic changes in cytogenetically abnormal myelodysplastic syndromes.
    Szczarkowski, W
    Stelzer, G
    Shults, K
    Stone, E
    Mixon, C
    Braylan, RC
    BLOOD, 1997, 90 (10) : 4052 - 4052
  • [39] Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.
    Santini, Valeria
    Sanna, Alessandro
    Duca, Lorena
    Gozzini, Antonella
    Girelli, Domenico
    Cortelezzi, Agostino
    Reda, Gianluigi
    Campostrini, Natascia
    Cappellini, Maria Domenica
    BLOOD, 2009, 114 (22) : 696 - 696
  • [40] Functional disturbance of marrow microenvironment in myelodysplastic syndromes.
    Tauro, S
    Hepburn, MD
    Peddie, CM
    Bowen, DT
    Pippard, MJ
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 455 - 455